Sihuan Pharmaceutical Holdings Group (HKG:0460) said its unit Huisheng Biopharmaceutical's obesity medicine was awarded an Investigational New Drug approval by China's National Medical Products Administration (NMPA).
The injection is a once-weekly formulation of GLP-1RA, used for long-term weight management, according to a Friday filing on the Hong Kong bourse.
Shares of the company rose by almost 2% on Friday's close.
Price (HKD): $0.54, Change: $+0.010, Percent Change: +1.89%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments